Peptide ACTH<sub>4-7</sub>-PGP: Effects on Various Types of Pain and Pain-Induced Behavior in Rats after Systemic and Central Administration.
Severyanova. L A LA; Kryukov. A A AA; Plotnikov. D V DV; Dolgintsev. M E ME
Key Findings
- Systemic (intraperitoneal) Semax increased pain sensitivity in the hot‑plate test.
- Both systemic and central (intracerebroventricular) Semax reduced pain‑related behavior in foot‑shock and tail‑shock models.
- Central administration produced a stronger analgesic effect than systemic dosing.
Practical Outcomes
- The results are from animal experiments and show inconsistent pain effects, so they don't provide clear guidance for human use. Biohackers should treat this as preliminary data and not base dosing or protocols on it without human studies.
Summary
In rats, the peptide Semax (ACTH4‑7‑PGP) showed mixed effects on pain: it made them more sensitive to a hot plate test but reduced pain‑related reactions in other shock‑based tests, especially when given directly into the brain.
Abstract
The effects of peptide ACTH4-7-PGP (Semax) were studied in 12 min after its intraperitoneal (in doses of 5, 15, 50, 150, and 450 μg/kg) or intracerebroventricular (in doses of 16, 40, and 400 pg) administration to rats with different types of pain and pain-induced behavior. It was found that the peptide increased pain sensitivity and induced avoidance behavior during thermal stimulation ("hot plate" test), but had an analgesic effect (more pronounced after central administration) and weakened emotional-affective behavior in electrocutaneous stimulation of the paws (foot-shock model) and tail in rats. It was shown that changes in activity of supraspinal brain structures were of primary importance in the mechanism of action on the nociceptive process and the formation of behavior.
Study Information
pubmed
2020
2020-12-02T00:00:00.000Z
10.1007/s10517-020-05029-8
13